Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study. This
study is designed to determine whether treatment with ALLN-177 for 28 days can reduce urinary
oxalate excretion in patients with enteric hyperoxaluria and to evaluate the safety of
ALLN-177 in this patient population compared to placebo.

Inclusion Criteria:

1. Provided informed consent

2. Age 18 or older

3. History of hyperoxaluria secondary to a known underlying enteric disorder associated
with malabsorption (e.g., bariatric surgery, Crohn's disease, short bowel syndrome, or
other malabsorption syndrome)

4. Urinary Oxalate ≥ 50mg/24h

Exclusion Criteria:

1. Acute renal failure or estimated glomerular filtration rate (eGFR) < 30mL/min/1.73 m2

2. Unable or unwilling to discontinue Vitamin C supplementation